Rome, April 16 (beraking latest news Health) – Due to the ongoing pandemic, millions of health care services have been postponed or not carried out, including hospitalizations, diagnostic tests, specialist visits, with important consequences for the chronically ill, such as people with haemophilia. From the survey, conducted last year by Bhave, to assess the social impact of Covid-19 on people with haemophilia, out of 142 respondents, 73% said they had decided not to carry out or postpone urgent scheduled visits, the 37% of not having carried out the rehabilitation activities and 22% of not having respected the indications for therapy received from their center. 60% of the respondents also reported that their doctor, during the lockdown, provided specific suggestions regarding the management of haemophilia and coronavirus, such as medications and protections, mostly remotely: by phone (63%), WhatsApp (60%) and e-mail (30%).
“This survey shows how telemedicine can satisfy patients in this pandemic context, but also how it can represent a solution to simplify the life of people with haemophilia in general, improving access to care and at the same time reducing the burden for health facilities, so that they can devote more attention to patients with more critical or acute conditions. More generally, the widespread implementation of telemedicine could not only improve direct care of patients with haemophilia, but ensure adequate home care and enable more people, especially those living in disadvantaged areas, to receive specialized hematological care. ”, Comments Lucio Corsaro, Founder & Advisor Bhave.
Precisely to simplify and improve the lives of people with haemophilia, Novo Nordisk promotes a nursing and physiotherapy support program both at home and at a distance, which has been intensified since last year to bring concrete help during the coronavirus emergency. At the same time, thanks to this program, the specialist is also helped in the management of their patients, through a web platform that allows them to monitor the patient’s progress through documentation of home activities.
“Novo Nordisk has always been committed to driving change in haemophilia and other rare coagulation disorders, addressing the unmet needs of people with haemophilia and their medical specialists,” said Drago Vuina, General Manager & Corporate Vice President of Novo Nordisk. Italy.
“Novo Nordisk – he adds – invests in the research and development of innovative, effective and safe drugs and we are obtaining excellent results from the experimentation of a new monoclonal antibody which, we hope, will allow us to reach a new normal of life for people with haemophilia, overcoming difficulties and fears; in addition, for more than 30 years, with the Changing Haemophilia * project, our company has been collaborating with national and international partners to support access to diagnosis and treatment at a multidisciplinary level. “
In this context, in Italy, Novo Nordisk promotes Haemophilia * Dialogue, a project of continuous dialogue to encourage the creation of networking activities, advocacy projects and partnerships aimed at involving patient associations, scientific societies, administrators, health authorities. and policy makers, to develop a roadmap to facilitate access to care and achieve lasting and meaningful change for people with haemophilia.